Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering…
BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update
Continued execution of BioNTech’s oncology strategy with focus on two pan-tumor programs…
Erin M. Schuman Wins 2026 Nakasone Award for Discovery on Neural Synapse Function and Change During Formation of Memories
STRASBOURG, France, July 9, 2025 /PRNewswire/ -- The International Human Frontier Science…